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remain after (or have been selected by)
treatment.
A prevailing view of carcinogenesis is of
a stepwise accumulation of transforming
genetic changes that arise in the progeny
of an initially normal cell that has been
exposed to some mutagenizing event.
This ‘‘linear progression’’ of sequentially
more mutated progeny is thought to
culminate in a cell capable of sustaining
the cancer (the CSC).
However, the variability in tumor-initi-
ating capacities observed when the
various cellular compartments of pretreat-
ment cancer tissues are tested in
different mouse recipients could imply
that cells capable of sustaining cancer
are heterogeneous and that multiple
subclones capable of tumor initiation arise
in parallel (as opposed to a strict linear
evolution) and compete for dominance
in a Darwinian fashion. Molecular genetic
evidence for such heterogeneity has
come from the study of lymphoid malig-
nancies where global sequencing ex-
poses molecular variability within indi-
vidual tumors, suggesting that they are
comprised of interrelated subclones de-
rived from common ancestors (Campbell
et al., 2008). Those clones that win the
initial battle of selection during carcino-
genesis may not be the ones that
survive/are selected by chemotherapy
and which drive relapse.
Circumstantial evidence for the emer-
gence of relapse propagating clones
(RPCs) has come from single-nucleotide
polymorphism studies of paired diag-
nostic and relapse samples from patients
with childhood leukemia (Mullighan et al.,
2008). Here, the genetic abnormalities
that were dominant at the time of disease
relapse often differed from those detected
at presentation, when they represented
a minor component of the disease.
The functional and molecular character-
ization of RPCs would be subject to the
same limitations as for CSCs and would
additionally require diligent archiving of
matched diagnostic, remission, and re-
lapse material.
This notion serves to underline the fact
that patients represent the best ‘‘test
tubes’’ for such work and may point the
way forward for this fascinating field.
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The human embryonic stem cell (hESC) transcriptome is well described, but minimal proteome characteriza-
tion is available. In this issue of Cell Stem Cell, Brill et al. (2009) and Van Hoof et al. (2009) describe the hESC
phosphoproteome and its changes upon differentiation.Human embryonic stem cells (hESCs) are
capable of differentiation into all lineages
of the body, but directed differentiation
to pure populations of cells has proven
difficult to accomplish. Ideally, hESCs
could be coerced to a particular lineage
by making a series of changes to their126 Cell Stem Cell 5, August 7, 2009 ª2009culture environment. These changes
could be mediated via the application
of growth factors, small molecules, and
other effectors of cellular response, re-
sulting ultimately in a signaling cascade(s)
that directs differentiation along a partic-
ular path. Major transducers of theseElsevier Inc.environmental stimuli are the protein
kinases, which transfer information by
adding phosphate groups to Ser, Thr,
and Tyr residues of proteins to create
differences in the biochemical properties
of their targets and thus their binding
affinities (Pawson and Nash, 2003).
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Figure 1. Comparison of the Two Phosphoproteomic Studies
A comparison between the phosphopeptides identified in Brill et al. (2009) and Van Hoof et al. (2009).
Phosphopeptides identified in either study were overlapped via their gene symbol.
(A) Venn diagram showing the overlap of gene symbols between the two phosphoproteome studies and
a selected list of phosphoproteins identified in both studies.
(B) A Venn diagram of the overlap between phosphoproteins identified as being upregulated in both
studies when hESCs were differentiated with retinoic acid or BMP4, and a selected list of phosphoproteins
identified in either one or both phosphoprotein list.Identifying these information transfer
points and how they change in response
to stimuli is key to understanding and
manipulating the biology of a cell. The
interrogation of the phosphoproteome
has been successful in helping unravel
the role of cell signaling in controlling cell
behavior in other cell types (Olsen et al.,
2006). The characterization of the hESC
phosphoproteome would provide an
invaluable resource in designing rational
approaches that bring about changes in
cellular differentiation (or maintain pluri-
potency) and so allow precise control of
hESC fate.
Comprehensive analyses of the hESC
transcriptome and its regulation have
yielded significant insight into the nature
of pluripotency, but control at this level
is only part of the story. Often it is
assumed that if mRNA is present, so too
is the protein. However, recent evidence
suggests that substantial regulation of
protein synthesis is mediated via transla-
tional control, at least during mouse ESC
differentiation (Sampath et al., 2008).Thus, it is essential to describe the pro-
teome to uncover the functional units of
the hESC protein-coding transcriptome.
There has recently been some character-
ization of the hESC proteome (Swaney
et al., 2008); however, to date, a system-
atic study of the hESC phosphoproteome
has not been reported. In this issue, two
independent research groups remedy
this situation by using mass spectrometric
approaches to analyze the phosphopro-
teome of hESCs, as well as tracking
dynamic changes to these profiles upon
exposure to differentiating stimuli (Brill
et al., 2009; Van Hoof et al., 2009).
In one case, Ding and colleagues took
advantage of multidimensional liquid
chromatography-based mass spectrom-
etry to identify phosphorylated peptides.
The authors performed this analysis for
two populations: undifferentiated hESCs
(WiCell’s H1 line) and hESCs differenti-
ated for 4 days by the addition of retinoic
acid. They identify 2546 phosphorylation
sites on 1662 proteins (Brill et al., 2009).
Krijgsveld and colleagues, in contrast,Cell Stem Ceused stable isotope labeling by amino
acids in cell culture (SILAC) to measure
relative quantitation of the phosphopro-
teins present in Harvard’s HUES-7 hESC
line and how the levels of these phospho-
proteins change upon induction of differ-
entiation with addition of BMP4 for 30,
60, and 240 min. The authors identify
a total of 5222 proteins of which 1399 of
these contained a total of 3067 phosphor-
ylation sites (Van Hoof et al., 2009). A third
phosphoproteome study was recently
described providing a collective analysis
of 10,844 unique phosphosites in undif-
ferentiated hESC (Swaney et al., 2009),
though specific phosphorylation sites
were not disclosed and dynamic changes
were not analyzed.
Kinase-mediated signaling events occur
very rapidly (often on the order of seconds
to minutes; Olsen et al., 2006), so neither
group aimed to identify the primary
events occurring upon the addition of
their respective differentiation stimuli.
The differentiated state was used rather
as a reference to uncover phosphopro-
teins enriched or reduced in the undiffer-
entiated state. The Van Hoof study,
however, with its shorter time course
of differentiation, was able to capture
the cascade of phosphorylation events
downstream of BMP/Smad signaling.
Note, though, that both studies remove
FGF2 from the differentiation media so
that the interpretation of the data must
take into account the loss of this receptor
tyrosine kinase activator. Interestingly,
both studies find significantly higher inci-
dence of phosphorylation in the differenti-
ating cells. This trend is perhaps not
surprising, given that the comparison
was between a cell population experi-
encing the dynamic changes that accom-
pany differentiation (and presumably that
require significant intracellular communi-
cation) and one in a relatively stable
phenotype. In total, the Ding and Krijgs-
veld groups characterized 929 and 1091
phosphorylation sites, respectively, that
exhibited differences between the undif-
ferentiated and differentiated states.
Both groups probed the phosphopro-
teome of undifferentiated hESCs, so one
might expect to detect some overlap
between data sets. Indeed, an overlap
between the two studies is observed,
and the specific hits include transcription
factors, epigenetic modifiers, as well
as many other functional classes ofll 5, August 7, 2009 ª2009 Elsevier Inc. 127
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significant differences between the
methods used, and the analysis of distinct
hESC lines between studies, the 35%
overlap detected seems to be of some
significance, and in line with previous
comparisons (Olsen et al., 2006). At the
same time, given the different methods
of differentiation utilized by the two
groups, the fact that BMP4 induction
promotes extraembryonic lineages (Xu
et al., 2002; Pera et al., 2004) whereas ret-
inoic acid directs hESCs toward an ecto-
derm cell fate (Wichterle et al., 2002),
and differing time points examined in
each case, it should not be surprising
that we see much less overlap (7%)
between the two differentiated data sets
(Figure 1B). However, it is interesting to
note that a significant number of protein
synthesis and translation regulators are
found differentially phosphorylated within
only 240 min of differentiation (a majority
within as few as 30 min) (Figure 1B). This
pattern implies that FGF removal and/or
addition of BMP4 also regulate the cell
at the translational level in addition to the
transcriptional level.
Needless to say, both papers provide
a substantial amount of data that stem
cell scientists can mine for the purposeCD95/Fas in the B
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Although CD95 (Fas/Apo-1) has lo
remained enigmatic. In this issue ofC
activator of neurogenesis in both th
CD95 is the best characterized and para-
digmatic member of the TNF-receptor
superfamily of ‘‘death receptors,’’ and the
molecular mechanism of CD95-induced
apoptosis is known specifically. After
binding of CD95L, CD95 forms trimers and
sequentially recruits the adaptor protein
FADD, regulatory proteins (like DAXX or
128 Cell Stem Cell 5, August 7, 2009 ª2009of developing new hypotheses. These
models can then be tested for their
potential roles in the control of the undif-
ferentiated state or in the initial steps of
differentiation. Brill et al. (2009) undertake
this approach by identifying additional
receptor tyrosine kinases activated in
hESCs and, in doing so, reveal an effect
of PDGF in the maintenance of pluripo-
tency. Meanwhile, Van Hoof et al. (2009)
identify a phosphorylation site on Sox2
that mediates SUMOylation, potentially
providing a mechanism to overcome the
stem cell regulatory circuitry during the
initial phase of differentiation.
Many of the phosphorylation sites
identified in these studies remain unchar-
acterized, and their functions unknown,
and yet describing these data sets is
only an initial step in characterizing the
hESC phosphoproteome, given that Swa-
ney et al. (2009) have recently identified
thousands more sites. Ultimately these
types of studies will provide sufficient
phosphoproteome resources to allow
the stem cell community to integrate
cellular regulation at all levels of control
and achieve mastery over the hESC and
its fate choices. It may be a daunting
task, but it is exciting to see the progress
made thus far.rain—Not Just a K
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FLIP), and procaspase 8, leading to the
formation of a death-inducing complex
(DISC). The oligomerization then results
in the autoproteolytic cleavage of procas-
pase 8 and the initiation of the apoptotic
cascade (Peter and Krammer, 2003). In
the central nervous system, CD95 expres-
sion varies significantly during develop-
Elsevier Inc.REFERENCES
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ssed in the brain, its function has
show that CD95 serves as a potent
ment. In the adult brain, neurons in the
hippocampus and cerebral cortex show
the highest CD95 expression, although
CD95 expression is also detectable on
astrocytes and oligodendrocytes espe-
cially under pathological conditions. Con-
versely, the cognate ligand CD95L is
constitutively coexpressed on neurons
